Braun Stacey Associates Inc. Makes New Investment in Insulet Corporation $PODD

Braun Stacey Associates Inc. acquired a new position in shares of Insulet Corporation (NASDAQ:PODD) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 53,952 shares of the medical instruments supplier’s stock, valued at approximately $16,657,000. Braun Stacey Associates Inc. owned approximately 0.08% of Insulet at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. increased its holdings in Insulet by 0.5% during the 2nd quarter. Vanguard Group Inc. now owns 8,708,355 shares of the medical instruments supplier’s stock valued at $2,735,991,000 after purchasing an additional 39,403 shares in the last quarter. Geode Capital Management LLC boosted its stake in Insulet by 3.1% in the second quarter. Geode Capital Management LLC now owns 1,927,543 shares of the medical instruments supplier’s stock worth $603,211,000 after purchasing an additional 58,309 shares in the last quarter. Norges Bank bought a new stake in shares of Insulet during the second quarter worth $324,689,000. Federated Hermes Inc. increased its stake in shares of Insulet by 14.3% in the second quarter. Federated Hermes Inc. now owns 723,363 shares of the medical instruments supplier’s stock valued at $227,266,000 after buying an additional 90,494 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its holdings in shares of Insulet by 1.0% in the second quarter. Charles Schwab Investment Management Inc. now owns 681,130 shares of the medical instruments supplier’s stock valued at $213,997,000 after buying an additional 6,763 shares during the last quarter.

Insulet Price Performance

Shares of PODD opened at $284.24 on Friday. The stock has a market cap of $20.00 billion, a P/E ratio of 82.39, a price-to-earnings-growth ratio of 2.00 and a beta of 1.40. Insulet Corporation has a 1 year low of $230.05 and a 1 year high of $354.88. The stock’s 50-day moving average price is $310.36 and its two-hundred day moving average price is $312.37. The company has a current ratio of 2.87, a quick ratio of 2.18 and a debt-to-equity ratio of 0.68.

Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 EPS for the quarter, beating analysts’ consensus estimates of $1.13 by $0.11. Insulet had a return on equity of 24.36% and a net margin of 9.76%.The company had revenue of $521.70 million during the quarter, compared to analysts’ expectations of $678.70 million. During the same period in the prior year, the business posted $1.08 EPS. Insulet’s revenue was up 29.9% on a year-over-year basis. On average, equities analysts predict that Insulet Corporation will post 3.92 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts have commented on the stock. Raymond James Financial increased their price objective on shares of Insulet from $366.00 to $385.00 and gave the stock an “outperform” rating in a report on Friday, November 21st. Wolfe Research increased their price target on shares of Insulet from $350.00 to $375.00 and gave the company an “outperform” rating in a research note on Friday, November 7th. Rothschild & Co Redburn boosted their price objective on shares of Insulet from $350.00 to $370.00 and gave the stock a “buy” rating in a research report on Friday, October 3rd. Leerink Partners lifted their price objective on Insulet from $385.00 to $386.00 and gave the stock an “outperform” rating in a research report on Friday, November 21st. Finally, JPMorgan Chase & Co. boosted their price objective on Insulet from $340.00 to $415.00 and gave the stock an “overweight” rating in a report on Friday, September 12th. One analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, Insulet has an average rating of “Moderate Buy” and an average price target of $379.00.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.